{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":5,"youtube":4,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03872401\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"VESALIUS-CV","nct_id":"NCT03872401","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=vesalius-cv-nct03872401. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"VESALIUS-CV","arms":[{"description":"Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W).","label":"Placebo","type":"PLACEBO_COMPARATOR"},{"description":"Participants will receive 140 mg evolocumab by subcutaneous injection Q2W.","label":"Evolocumab 140 mg Q2W","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-07-25","type":"ACTUAL"},"conditions":["Coronary Heart Disease (CHD)"],"enrollment":{"count":12301,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Evolocumab","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-06-25","lead_sponsor":"Amgen","official_title":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First","timeFrame":"From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months"},{"measure":"Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First","timeFrame":"From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months"}],"references":[{"citation":"Bohula EA, Marston NA, Ruzza A, Murphy SA, De Ferrari GM, Diaz R, Leiter LA, Elliott-Davey M, Wang H, Bhatia AK, Giugliano RP, Sabatine MS. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. Am Heart J. 2024 Mar;269:179-190. doi: 10.1016/j.ahj.2023.12.004. Epub 2023 Dec 29.","pmid":"38160917","type":"BACKGROUND"},{"citation":"Giugliano RP, Bohula EA, Bellavia A, De Ferrari GM, Leiter A, Nicolau JC, Bhatia AK, Murphy SA, Liu L, Wang H, Blaha V, Erglis A, Ferreira J, Goudev A, Jensen HK, Kiss RG, Montalescot G, Parkhomenko A, Sattar N, Sinnaeve P, Slapikas R, Paiva da Silva Lima G, Sabatine MS; VESALIUS-CV Investigators. Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial. Circulation. 2026 Aug 31. doi: 10.1161/CIRCULATIONAHA.126.082436. Online ahead of print.","pmid":"42670293","type":"DERIVED"},{"citation":"Nicolau JC, Murphy SA, Giugliano RP, Leiter LA, De Ferrari GM, Park JG, Kuder J, Liu L, Wang H, Shastri-Kumar V, Averkov O, Blaha V, Dzupina A, Ferreira J, Kuusisto J, Lopez-Sendon J, Lorenzatti AJ, Nicholls S, Pella D, Slapikas R, Tokgozoglu L, Vinereanu D, Cyrille M, Sabatine MS, Bohula EA. Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study. J Am Coll Cardiol. 2026 Aug 28:S0735-1097(26)07440-1. doi: 10.1016/j.jacc.2026.08.015. Online ahead of print.","pmid":"42663360","type":"DERIVED"},{"citation":"Monguillon V, Marston NA, Bohula EA, Park JG, Kuder JF, Murphy SA, De Ferrari GM, Leiter LA, Nicolau JC, Ebenbichler C, Sinnaeve P, Goudev A, Budaj A, Averkov O, Tokgozoglu L, Blankstein R, Vinereanu D, Giugliano RP, Sabatine MS, O'Donoghue ML. Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial. Circulation. 2026 Jun 23;153(25):1960-1968. doi: 10.1161/CIRCULATIONAHA.126.080999. Epub 2026 May 25.","pmid":"42183757","type":"DERIVED"},{"citation":"Bergmark BA, Bohula EA, Marston NA, Park JG, Kuder JF, Murphy SA, De Ferrari G, Leiter LA, Nicolau JC, Averkov O, Charng MJ, Ebenbichler C, Erglis A, Gouni-Berthold I, Montalescot G, Nicholls SJ, Sigurdsson A, Sinnaeve PR, Slapikas R, Tsioufis K, Verma S, Viigimaa M, Bhatia A, Xin L, Walsh E, Ohman EM, Giugliano RP, Sabatine MS. Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial. Circulation. 2026 Jul 7;154(1):28-36. doi: 10.1161/CIRCULATIONAHA.126.080616. Epub 2026 May 19.","pmid":"42153665","type":"DERIVED"},{"citation":"Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026 Apr 28;335(16):1400-1407. doi: 10.1001/jama.2026.3277.","pmid":"41903215","type":"DERIVED"},{"citation":"Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026 Jan 8;394(2):117-127. doi: 10.1056/NEJMoa2514428. Epub 2025 Nov 8.","pmid":"41211925","type":"DERIVED"}],"start_date":{"date":"2019-06-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","url":"https://clinicaltrials.gov/study/NCT03872401"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/vesalius-cv-nct03872401"}